Radiopharm Theranostics CMO acquires three option awards

The three option awards have exercise dates in 2027, 2028 and 2029, with all three expiring July 1, 2031.

Rhea-AI Filing Summary

Radiopharm Theranostics Ltd (RADX) Chief Medical Officer Dimitris Voliotis acquired three direct option awards on October 19, 2026: two covering 10,295,667 Ordinary Shares each and one covering 10,295,666 Ordinary Shares. Each has an A$0.0210 exercise price. Their exercise dates are July 1, 2027, July 1, 2028, and July 1, 2029, respectively, and all expire July 1, 2031.

Insider Trade Summary

Grant/Award: 30,887,000 shares

Grant/Award 3 txns

Insider Voliotis Dimitris

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Option (Right to buy)	10,295,667	$0.00	$0.00
Grant/Award	Option (Right to buy)	10,295,667	$0.00	$0.00
Grant/Award	Option (Right to buy)	10,295,666	$0.00	$0.00

Holdings After Transaction: Option (Right to buy) — 30,887,000 contracts (Direct)

Key Figures

Underlying shares per first option award: 10,295,667 Ordinary Shares Underlying shares per second option award: 10,295,667 Ordinary Shares Underlying shares in third option award: 10,295,666 Ordinary Shares +2 more

5 metrics

Underlying shares per first option award 10,295,667 Ordinary Shares Exercise date July 1, 2027

Underlying shares per second option award 10,295,667 Ordinary Shares Exercise date July 1, 2028

Underlying shares in third option award 10,295,666 Ordinary Shares Exercise date July 1, 2029

Exercise price A$0.0210 per share Applies to the three option awards

Option expiration date July 1, 2031 Applies to the three option awards

Key Terms

Option (Right to buy), exercise price, beneficially owned

3 terms

Option (Right to buy) financial

"Option (Right to buy)"

exercise price financial

"All exercise prices are in Australian dollars."

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

beneficially owned financial

"There are no non-derivative securities beneficially owned."

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many RADX options did Chief Medical Officer Dimitris Voliotis acquire?

Dimitris Voliotis acquired three direct option awards on October 19, 2026: two covering 10,295,667 Ordinary Shares each and one covering 10,295,666 Ordinary Shares.

What are the exercise price and dates for the RADX options?

Each option has an A$0.0210 exercise price. The exercise dates are July 1, 2027, July 1, 2028, and July 1, 2029, respectively, and all three expire July 1, 2031.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/27/2026 - 07:08 PM EDT Accepted by SEC EDGAR 10/27/2026 - 07:08 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Voliotis Dimitris

(Last) (First) (Middle)

SUITE 1, LEVEL 3, 62 LYGON STREET

(Street)

CARLTON SOUTH, VICTORIA NEW YORK 3053

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Radiopharm Theranostics Ltd [ RADX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option (Right to buy)	$0.021	10/19/2026		A		10,295,667		07/01/2027	07/01/2031	Ordinary Shares	10,295,667	$0.00	10,295,667	D
Option (Right to buy)	$0.021	10/19/2026		A		10,295,667		07/01/2028	07/01/2031	Ordinary Shares	10,295,667	$0.00	10,295,667	D
Option (Right to buy)	$0.021	10/19/2026		A		10,295,666		07/01/2029	07/01/2031	Ordinary Shares	10,295,666	$0.00	10,295,666	D

Explanation of Responses:

Remarks:

All exercise prices are in Australian dollars. There are no non-derivative securities beneficially owned.

	/s/ Dimitris Voliotis	10/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)